2-FA

At approximately 5 mg oral, 2-FA produces barely perceptible stimulation — a subtle increase in wakefulness and alertness without clear cognitive enhancement or mood elevation. Most users report minimal subjective change at this level, with effects easily attributable to placebo or expectation. Physical effects are negligible. No appreciable cardiovascular activation, appetite suppression, or pupil dilation is expected at threshold doses. The experience is sub-functional and primarily useful for assessing individual sensitivity before titrating upward. Duration at threshold is brief, typically resolving within 1–2 hours. Sleep disruption is unlikely at this dose level.

At 15–30 mg oral, 2-FA produces mild functional stimulation. Wakefulness becomes noticeable, with subtle focus enhancement and a slight sharpening of attention. Thought acceleration is minimal. Cognitive euphoria is absent or barely perceptible — the experience is utilitarian rather than hedonic. Physical effects remain mild. Slight appetite suppression may emerge. Cardiovascular changes (heart rate, blood pressure) are minimal at this range. Pupil dilation is possible but subtle. Side effects such as bruxism, muscle tension, or excessive sweating are uncommon at light doses. Comparable in character to a low therapeutic dose of amphetamine. Duration is 2–3 hours. Sleep disruption is unlikely if taken early in the day.

At 30–50 mg oral, 2-FA produces its characteristic stimulant profile. Focus enhancement, motivation enhancement, and thought acceleration are clearly present. Wakefulness is pronounced. Cognitive euphoria is possible but described as modest — a mild sense of clarity and drive rather than overt pleasure. The experience is consistently described as functional rather than recreational. Appetite suppression is moderate. Heart rate elevation becomes noticeable. Mild excessive sweating, dehydration sensation, and pupil dilation are common. Bruxism and muscle tension may appear but are less prominent than with more serotonergic stimulants like 4-FA. This is the dose range most commonly reported for productive use. Total duration is 2–4 hours, with the short duration creating potential temptation to redose. Insomnia is possible if taken in the afternoon or evening.

At 50–60 mg oral, 2-FA shifts toward side-effect dominance. Stimulation is pronounced but the desirable cognitive effects — focus enhancement, thought organization — do not scale proportionally with dose. Anxiety and restlessness become prominent. Cognitive euphoria, if present at common doses, does not meaningfully increase. Physical effects intensify: excessive sweating, muscle tension, insomnia, vasoconstriction, and elevated heart rate are common. Temperature dysregulation and headache may emerge. Appetite suppression is strong. The cardiovascular stress at this tier warrants caution in anyone with borderline cardiovascular health. Diminishing returns on desirable effects with increasing adverse effects define this tier. The compulsive redosing urge may be stronger due to the short duration, but escalating dose produces more side effects rather than greater reward.

Doses above 60 mg oral produce strong sympathomimetic activation with a high adverse-effect burden. Marked anxiety, paranoia potential, pronounced insomnia, vasoconstriction, and temperature dysregulation are expected. Cardiovascular stress is significant — tachycardia and hypertension may reach clinically concerning levels. Risk of stimulant psychosis increases substantially at this tier, particularly with prolonged use, repeated dosing, or concurrent sleep deprivation. Delusions and tactile hallucinations become possible under extreme conditions. The compulsive redosing urge may lead to cumulative dose escalation that compounds all risks. No published safety data exist at these doses. The exact toxic threshold is unknown. Heavy doses of 2-FA represent an uncharacterized risk space where acute cardiovascular emergencies and psychotic episodes become plausible outcomes.